1) Kidney Disease. Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013 ; 3 : 1-150.
2) Kondo M, Yamagata K, Hoshi SL, et al. Cost-effectiveness of chronic kidney disease mass screening test in Japan. Clin Exp Nephrol. 2011 ; 16 : 279-91.
3) 石田久美子. 成人検尿および血清クレアチニン測定の意義と現状 (茨城県の健診データを中心に). 日内会誌. 2001 ; 90 : 1199-206.
4) Konta T, Hao Z, Abiko H, et al. Prevalence and risk factor analysis of microalbuminuria in Japanese general population : the Takahata study. Kidney Int. 2006 ; 70 : 751-6.
5) Iseki K, Asahi K, Moriyama T, et al. Risk factor profiles based on estimated glomerular filtration rate and dipstick proteinuria among participants of the Specific Health Check and Guidance System in Japan 2008. Clin Exp Nephrol. 2012 ; 16 : 244-9.
6) Nagata M, Ninomiya T, Doi Y, et al. Trends in the prevalence of chronic kidney disease and its risk factors in a general Japanese population : the Hisayama Study. Nephrol Dial Transplant. 2010 ; 25 : 2557-64.
7) Irie F, Iso H, Sairenchi T, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006 ; 69 : 1264-71.
8) Nakayama T, Date C, Yokoyama T, et al. A 15.5-year follow-up study of stroke in a Japanese provincial city. The Shibata Study. Stroke. 1997 ; 28 : 45-52.
9) Madison JR, Spies C, Schatz IJ, et al. Proteinuria and risk for stroke and coronary heart disease during 27 years of follow-up : the Honolulu Heart Program. Arch Intern Med. 2006 ; 166 : 884-9.
10) 井関邦敏. 疫学調査から見た慢性腎疾患対策の重要性. 日内会誌. 2005 ; 94 : 163-8.
11) de Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria : public health perspectives. J Am Soc Nephrol. 2006 ; 17 : 2120-6.
12) Sugiyama H, Yokoyama H, Sato H, et al. Japan Renal Biopsy Registry : the first nationwide, web-based, and prospective registry system of renal biopsies in Japan. Clin Exp Nephrol. 2011 ; 15 : 493-503.
13) Sugiyama H, Yokoyama H, Sato H, et al. Committee for Standardization of Renal Pathological Diagnosis and Committee for Kidney Disease Registry, Japanese Society of Nephrology. Japan Renal Biopsy Registry and Japan Kidney Disease Registry : Committee report for 2009 and 2010. Clin Exp Nephrol. 2013 ; 17 : 155-73.
14) 厚生労働科学研究費補助金難治性疾患克服研究事業 : 進行性腎障害に関する調査研究 平成24年度総括・分担研究報告書. 研究代表者 : 松尾清一. 2013. p.73.
15) 横山仁, 杉山斉, 佐藤博. 腎臓病総合レジストリー (J-RBR/J-KDR) の経緯と展望. 日腎会誌. 2017 ; 59 : 1042-8.
16) 丸山彰一. エビデンスに基づくネフローゼ症候群診療ガイドライン 2017. 東京 : 東京医学社 ; 2017.
17) Floege J, Feehally J. Introduction to glomerular disease. In : Feehally J, et al. editors. Clinical presentation. Clinical Comprehensive Nephrology. 3rd ed. Mosby ; 2007 : p.193.
18) Chang JH, Kim DK, Kim HW, et al. Changing prevalence of glomerular diseases in Korean adults : a review of 20 years of experience. Nephrol Dial Transplant. 2009 ; 24 : 2406-10.
19) Kazi JI, Mubarak M, Ahmed E, et al. Spectrum of glomerulonephritides in adults with nephrotic syndrome in Pakistan. Clin Exp Nephrol. 2009 ; 13 : 38-43.
20) 丸山彰一, 他. 平成26年度厚生労働科学研究費補助金難治性疾患等政策研究事業「難治性腎疾患に関する調査研究」ネフローゼ症候群ワーキンググループ (山本陵平らによる解析).
21) 猪阪善隆, 他. 平成27年度厚生労働科学研究費補助金難治性疾患等政策研究事業「難治性腎疾患に関する調査研究」ネフローゼ症候群ワーキンググループ (山本陵平らによる解析).
22) Yokoyama H, Narita I, Sugiyama H, et al. Drug-induced kidney disease : a study of the Japan Renal Biopsy Registry from 2007 to 2015. Clin Exp Nephrol. 2015 ; 19 : 496-505.
23) Shiiki H, Saito T, Nishitani Y, et al. Research Group on Progressive Renal Diseases in Japan. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int. 2004 ; 65 : 1400-7.